A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 153-161

  Massaoka, Mariana H ^a   Matsuo, Alisson L ^a   Figueiredo, Carlos R ^a   Girola, Natalia ^a   Faria, Camyla F ^a   Azevedo, Ricardo A ^a   Travassos, Luiz R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Malignant melanoma; P53; Senescence; Wilms tumor 1 (WT1)

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CELL PENETRATING PEPTIDE; COMPLEMENT COMPONENT C3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LYSINE ARGININE RICH PEPTIDE; PROTEIN P53; UNCLASSIFIED DRUG; WT1 PROTEIN; WT1 PTJ PEPTIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL AGING; CELL SURVIVAL; CELL VIABILITY; CHEMOLUMINESCENCE; CLONOGENESIS; COLONY FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MELANOMA CELL; METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR LOCALIZATION; TUMOR VOLUME; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; DRUG EFFICACY; EC50; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; FIBROBLAST CULTURE; MELANOMA; METASTASIS INHIBITION; MOUSE; PROTEIN BINDING; PROTEIN DOMAIN; TRANSCRIPTION REGULATION; ZINC FINGER MOTIF;

EID: 84893400614     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2014.01.007     Document Type: Article

References (59)

1. Yang L., et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007, 21:868-876.
2. Call K.M., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
3. Pelletier J., et al. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991, 353:431-434.
4. Nakatsuka S., et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 2006, 19:804-814.
5. Oji Y., et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 1999, 90:194-204.
6. Wagner N., et al. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch. 2008, 455:839-847.
7. Zamora-Avila D.E., et al. RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res. 2007, 17:341-348.
8. Zamora-Avila D.E., et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 2009, 16:892-899.
9. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012, 2012:967347.
10. Giorello L., et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 1998, 58:3654-3659.
11. Bonfanti M., et al. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 1997, 57:1442-1446.
12. Rosca E.V., et al. Anti-angiogenic peptides for cancer therapeutics. Curr. Pharm. Biotechnol. 2011, 12:1101-1116.
13. Tan M., et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006, 66:3764-3772.
14. Cardo-Vila M., et al. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5118-5123.
15. Matsuo A.L., et al. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity. Mol. Cancer Res. 2011, 9:1471-1478.
16. Johansson H.J., et al. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol. Ther. 2008, 16:115-123.
17. Niesner U., et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 2002, 13:729-736.
18. Massodi I., et al. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin. Exp. Metastasis 2009, 26:251-260.
19. Caino M.C., Meshki J., Kazanietz M.G. Hallmarks for senescence in carcinogenesis: novel signaling players. Apoptosis 2009, 14:392-408.
20. Bringold F., Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol. 2000, 35:317-329.
21. Arruda D.C., et al. beta-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma. J. Biol. Chem. 2012, 287:14912-14922.
22. Massaoka M.H., et al. Melanoma: perspectives of a vaccine based on peptides. Molecular Vaccines: From Prophylaxis to Therapy 2013, 397-412. Springer-Verlag, Wien. M. Giese (Ed.).
23. Dobroff A.S., et al. Protective, anti-tumor monoclonal antibody recognizes a conformational epitope similar to melibiose at the surface of invasive murine melanoma cells. Hybrid Hybridomics 2002, 21:321-331.
24. Mhaidat N.M., et al. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer 2007, 97:1225-1233.
25. Hohenstein P., Hastie N.D. The many facets of the Wilms' tumour gene, WT1. Hum. Mol. Genet. 2006, 15(Spec No 2):R196-R201.
26. Zapata-Benavides P., et al. WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncol. Lett. 2012, 3:751-755.
27. Michiels J.F., et al. PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1. Pflugers Arch. 2010, 459:689-703.
28. Han Y., et al. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells. Breast Cancer Res. 2007, 9:R43.
29. Englert C. WT1-more than a transcription factor?. Trends Biochem. Sci. 1998, 23:389-393.
30. Maheswaran S., et al. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:5100-5104.
31. Maheswaran S., et al. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995, 9:2143-2156.
32. Itahana K., Dimri G., Campisi J. Regulation of cellular senescence by p53. Eur. J. Biochem. 2001, 268:2784-2791.
33. Larsson L.G. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin. Cancer Biol. 2011, 21:367-376.
34. Sviderskaya E.V., et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl. Cancer Inst. 2003, 95:723-732.
35. Wajapeyee N., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
36. Cozzi SJ., et al. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res. 2006, 66:10083-10091.
37. Kurz D.J., et al. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell. Sci. 2000, 113:3613-3622.
38. Bitler B.G., Schroeder J.A. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat. Anticancer Drug Discov. 2010, 5:99-108.
39. Roberts S.G. Transcriptional regulation by WT1 in development. Curr. Opin. Genet. Dev. 2005, 15:542-547.
40. Henderson E.J., Pentland B. Home pass assessment in neurorehabilitation practice. J. Adv. Nurs. 1991, 16:1439-1443.
41. Nardella C., et al. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11:503-511.
42. te Poele R.H., et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
43. Sidi R., et al. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur. J. Cancer 2011, 47:326-332.
44. Moiseeva O., et al. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol. Biol. Cell 2006, 17:1583-1592.
45. Webley K., et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 2000, 20:2803-2808.
46. Herbig U., et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
47. Di Micco R., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
48. Castellano M., et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 1997, 57:4868-4875.
49. FitzGerald M.G., et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8541-8545.
50. Innocente S.A., et al. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2147-2152.
51. McGowan C.H., Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993, 12:75-85.
52. Wells N.J., et al. The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. J. Cell. Sci. 1999, 112:3361-3371.
53. Deep G., et al. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006, 25:1053-1069.
54. Lin Y.Z., et al. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 1995, 270:14255-14258.
55. Selivanova G., et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 1997, 3:632-638.
56. Kanazawa T., et al. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles. Eur. J. Pharm. Biopharm. 2012, 81:470-477.
57. Grossman D., Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001, 20:3-11.
58. Jing H., et al. Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011, 25:2137-2146.
59. Schmitt C.A., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.